Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Formosa LaboratoriesTPE:4746 -0.57%76 EV-to-EBIT is 19.45 as of Aug. 20, 2026, which is 10% above its 10-year median of 17.65. GuruFocus rates TPE:4746 with a GF Score™ of 76/100 and a GF Value™ of NT$90.99 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 687 Drug Manufacturers companies, Formosa Laboratories ranks worse than 58.08% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Formosa Laboratories's Enterprise Value for the quarter that ended in Mar. 2026 was NT$8,834 Mil.
Formosa Laboratories's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$431 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Formosa Laboratories EV-to-EBIT Related Terms
Formosa Laboratories EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Formosa Laboratories's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Formosa Laboratories's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Formosa Laboratories EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Formosa Laboratories's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Formosa Laboratories's EV-to-EBIT falls into.
Formosa Laboratories's current Enterprise Value is NT$8,386 Mil.
Formosa Laboratories's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$431 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Formosa Laboratories (TPE:4746) has a EV-to-EBIT of 19.45 as of Aug. 20, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Formosa Laboratories and its competitors. This is 10% above median its historical median of 17.65. According to the industry distribution chart, Formosa Laboratories ranks #399 out of 687 companies in the Drug Manufacturers industry, placing it in the top 58.1%.
Is Formosa Laboratories' EV-to-EBIT too high?
Formosa Laboratories' current EV-to-EBIT of 19.45 is 10% above median its 10-year median of 17.65. The Drug Manufacturers industry median EV-to-EBIT is 15.81. Formosa Laboratories' value of 19.45 is 23% above this industry median. Based on the distribution chart, Formosa Laboratories ranks #399 out of 687 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Formosa Laboratories has a GF Score™ of 76/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Formosa Laboratories' EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Formosa Laboratories ranks #399 out of 687 companies for EV-to-EBIT. This places Formosa Laboratories in the lower half of its industry. The industry median EV-to-EBIT is 15.81. Formosa Laboratories' value of 19.45 is 23% above this benchmark. While the company's 10-year median is 17.65 vs. the industry median of 15.81, Formosa Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.81, based on 687 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Formosa Laboratories's current EV-to-EBIT of 19.45 is 23% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Formosa Laboratories and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Formosa Laboratories's current EV-to-EBIT is 19.45, which is 10% above median its own 10-year median of 17.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Formosa Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Formosa Laboratories (TPE:4746) is currently considered Possible Value Trap. The stock's GF Value™ is NT$90.99, compared to a current price of NT$52.00 — trading 42.9% below its estimated fair value. The current EV-to-EBIT is 19.45, which is 10% above median its 10-year median of 17.65 and 23% above the Drug Manufacturers industry median of 15.81. Formosa Laboratories' overall GF Score™ is 76/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Formosa Laboratories (TPE:4746), the current EV-to-EBIT is 19.45 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Formosa Laboratories (TPE:4746) Overvalued in 2026?
Based on GuruFocus' analysis, Formosa Laboratories stock appears to be undervalued.
The current stock price of NT$52.00 is trading 42.9% below its estimated GF Value™ of NT$90.99.
GuruFocus considers Formosa Laboratories to be Possible Value Trap.
Key valuation signals for TPE:4746:
EV-to-EBIT: 19.45 (10% above median its 10-year median of 17.65)
GF Value™: NT$90.99 vs. price of NT$52.00 (42.9% below fair value)
Industry Position: 23% above the Drug Manufacturers median (#399 of 687)
No single metric tells the full story. See the TPE:4746 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Formosa Laboratories Inc is mainly engaged in the wholesale and manufacturing of active pharmaceutical ingredients, as well as ultraviolet absorbers. The company geographically operates in India, Taiwan, Netherlands, Switzerland, Germany, Japan, China, Canada, United States, and Others.
76GF Score
Get the complete analysis for TPE:4746
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:4746 has been successfully added to your 
